AC Immune SA (ACIU) Stock Forecast: StockMap's 2-Week Call

ACIU stock forecast: StockMap's model leans Underperform on AC Immune SA for the two weeks after the Nov 13 close, toward ACIU trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 3 two-week windows on ACIU since Sep 24; by chance, a call on the same dates was right 51% of the time.

AC Immune SA last closed at $2.13, -0.47% on the session.

Against the IVW growth benchmark the position is +0.44% over the forecast window.

AC Immune SA's market cap is $216.77M as of November 13, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).

Where ACIU sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 daily calls for ACIU so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks AC Immune SA in the 10th percentile on return on equity, where 100 is best.

AC Immune SA is classified under Health Care / Biotechnology.

StockMap tracks AC Immune SA as the 231st largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.

On that composite AC Immune SA ranks 205th of 391 in the group, against a group median of -0.24.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 13, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

AC Immune SA (ACIU) — StockMap 2-week forecast & tracked accuracy